Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis.
|
31152798 |
2019 |
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Longitudinal data from the Kids-CAT study on children and adolescents with asthma, diabetes and juvenile arthritis (n = 248; aged 7-17 years) were assessed at three measurement points over six months.
|
29580563 |
2018 |
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tralokinumab (CAT-354) is an IL-13-neutralising human IgG4 monoclonal antibody that has shown clinical benefit in patients with asthma.
|
27956146 |
2017 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine the association of manganese superoxide dismutase (MnSOD) Ala16Val, catalase (CAT) A-21T and tumor necrosis factor alpha (TNF-α) G-308A polymorphisms with bronchial asthma.
|
25931357 |
2015 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The -262C>T and -21A>T polymorphisms in the CAT gene were genotyped in 493 individuals with asthma, 265 with COPD, and 1,076 healthy controls.
|
24824229 |
2014 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that catalase polymorphism might participate in development of bronchial asthma and in enhanced oxidative damage in asthmatic children.
|
23827365 |
2013 |
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this case study, we describe the use of in vitro protein evolution with ribosome display to improve the potency of a human interleukin-13-neutralising antibody by a factor of over 200-fold and derive a therapeutic candidate, CAT-354, for the treatment of asthma.
|
22094818 |
2012 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In our study, we did not find a significant association between Mn-SOD Ala16Val, CAT C-262T and asthma.
|
21829032 |
2011 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Notably, no association of CAT genotype -21AA with asthma was found in high fruit and vegetable consumers, whereas low fruit and vegetable consumers (one time per day or less often) possessing this genotype were at increased risk of both allergic (p = 0.013) and nonallergic (p = 0.008) asthma.
|
19373626 |
2009 |
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The individual effect of functional single nucleotide polymorphisms within the catalase and myeloperoxidase genes (CAT and MPO) has been studied in relation to asthma; however, their interrelationship with ambient air pollution exposures has yet to be determined.
|
19897513 |
2009 |
Asthma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In contrast, Hispanic children with a variant of the CAT-262 "T" allele (CT or TT) had an increased risk for asthma (HR, 1.78; P value = 0.01).
|
18048809 |
2008 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
In contrast, Hispanic children with a variant of the CAT-262 "T" allele (CT or TT) had an increased risk for asthma (HR, 1.78; P value = 0.01).
|
18048809 |
2008 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, Hispanic children with a variant of the CAT-262 "T" allele (CT or TT) had an increased risk for asthma (HR, 1.78; P value = 0.01).
|
18048809 |
2008 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The less frequent variant of catalase gene (-262T) was found to be protective from the development of asthma in a Hong Kong Chinese non-smoking population (adjusted odds ratio=0.35, 0.15-0.85; P=0.017).
|
16630148 |
2006 |
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In an application to asthma case-control data from the Children's Health Study, FITF identified a significant multilocus effect between the nicotinamide adenine dinucleotide (phosphate) reduced:quinone oxidoreductase gene (NQO1), myeloperoxidase gene (MPO), and catalase gene (CAT) (unadjusted P = .00026), three genes that are involved in the oxidative stress pathway.
|
16385446 |
2006 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Environmental lead exposure depresses the activities of a several enzyme systems that influence cellular reducing capacity (glucose-6-phosphate dehydrogenase, NAD synthetase, glutathione peroxidase, superoxide dismutase, catalase) and consequently may increase asthma risk.
|
8568107 |
1995 |